Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours (NET) of gastrointestinal or lung origin in adults with progressive disease; and for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease

Patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy

Disclaimer: This is an international web site for AFINITOR® (everolimus) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located. If you are living outside the US and are not a healthcare professional, click here.

You are now leaving the Afinitor.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.

This is an international site for AFINITOR® (everolimus) and is intended for healthcare professionals outside the United States. The information on the site is not country specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Below is a list of the countries that host an AFINITOR website based on local label and in a local language. They are intended for healthcare professionals (HCPs) only. If you are an HCP from one of the countries listed below, click on your country's link to be redirected to your country's AFINITOR website.

This website is intended for healthcare professionals (HCPs) outside the United States. The information on this website is not country-specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local Novartis representative for local prescribing information via www.NovartisOncology.com/contactus.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC).

This is an international site for AFINITOR® (everolimus) and is intended for healthcare professionals outside the United States.

AFINITOR® (everolimus) is approved for use in 121 countries around the world.